Audio: So, at ASCO 2022 this year I had the opportunity to present the results of the EA 2142 clinical trial this is a randomized phase two study of platinum and a…Read Full Transcript Here
Jennifer R. Eads, MD, Physician Lead GI Clinical Research, Associate Professor of Clinical Medicine, Director of the Neuroendocrine Tumor Program at the University of Pennsylvania. In this interview, she speaks about the ASCO 2022 Abstract – Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
Overview:
This randomized phase II trial compares the efficacy of temozolomide and capecitabine to standard treatment with cisplatin or carboplatin and etoposide in patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed surgically. Chemotherapy drugs including temozolomide, capecitabine, cisplatin, carboplatin, and etoposide function in multiple ways to inhibit tumor cell growth, either by killing the cells, preventing them from growing, or preventing them from spreading. Certain forms of neuroendocrine carcinomas may respond better to treatments other than cisplatin and etoposide, which are now the standard of care. It is unknown whether temozolomide and capecitabine are more effective than cisplatin or carboplatin and etoposide in the treatment of patients with this kind of neuroendocrine carcinoma, termed as non-small cell neuroendocrine carcinoma.